We conducted an open, prospective cohort study to evaluate its safety and effectiveness in Chinese participants infected with the omicron variant from March 8th, 2022 to March 24th, 2022. VV116 is an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies. Omicron variant of SARS-CoV-2 has become the predominant variant worldwide. 9 Key Laboratory of Medical Molecular Virology (MOE/MOH), Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.8 National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.7 Department of Respiratory Diseases, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, People's Republic of China.6 Department of Infectious Diseases, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, People's Republic of China.5 Department of Tuberculosis, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, People's Republic of China.
4 Lingang Laboratory, Shanghai, People's Republic of China.3 Department of COVID-19, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, People's Republic of China.2 Department of Infectious Diseases, National Medical Centre for Infectious Diseases, National Clinical Research Centre for Aging and Medicine, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.1 Department of Infection and Immunity, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, People's Republic of China.